Original Article

Apoptotic Events in Type-I Glanzmann Thrombasthenia Platelets

Abstract

Background: Activated normal platelets undergo numerous biochemical and morphological changes, some of which are apoptotic. Phosphatidylserine (PS) expression, Δψm depolarization, microparticle (MP) formation, platelet shrinkage, release of cytochrome c, and caspase activation are hallmarks of both platelet activation and apoptosis. In this study, we report the apoptotic responses of type-I Glanzmann thrombasthenic platelets.

Materials and Methods: Platelets from twelve unrelated patients with type I Glanzmann thrombasthenia were examined as washed platelets. Calcium ionophore A23187 was used as an agonist to activate the platelets. Flow cytometry was employed to detect phosphatidylserine expression (Annexin A5 Alexa Fluor), Δψm depolarization (JC-10), platelet-derived MP formation (forward scatter; events <1.0 µm in size), and platelet shrinkage (mean-FSC). Anti-CD42b was used as a platelet-specific marker to distinguish platelets from other particles.

Results: We determined that increased cytosolic calcium significantly increased PS exposure, depolarized mitochondrial inner membrane potential (Δψm), increased microparticle formation, and induced platelet shrinkage in type-I Glanzmann thrombasthenic platelets. Our research showed that type I Glanzmann thrombasthenic platelets exhibit characteristics of platelet apoptosis. GPIIbIIIa deficiency does not limit platelet activation or apoptosis.

Conclusion: We conclude that GPIIb-IIIa-independent mechanisms may be involved in the normal apoptosis of thrombasthenic platelets. Our data deepen the understanding of the role of the platelet fibrinogen receptor in revealing aspects of normal apoptosis. However, this may help explain the normal platelet count among thrombasthenic patients.

 

1. Gyulkhandanyan AV, Mutlu A, Freedman J, et al. Markers of platelet apoptosis: methodology and applications. J Thromb Thrombolysis. 2012;33(4):397-411.
2. Leytin V, Allen DJ, Mutlu A, et al. Mitochondrial control of platelet apoptosis: effect of cyclosporin A, an inhibitor of the mitochondrial permeability transition pore. Lab Invest. 2009;89(4):374-84.
3. Li Z, Delaney MK, O'brien KA, et al. Signaling during platelet adhesion and activation. Arterioscler Thromb Vasc Biol. 2010;30(12):2341-9.
4. Wolf BB, Goldstein JC, Stennicke HR, et al. Calpain functions in a caspase-independent manner to promote apoptosis-like events during platelet activation. Blood. 1999;94(5):1683-92.
5. Iraqi M, Perdomo J, Yan F, et al. Immune thrombocytopenia: antiplatelet autoantibodies inhibit proplatelet formation by megakaryocytes and impair platelet production in vitro. Haematologica. 2015;100(5):623-32.
6. Leytin V, Allen DJ, Mykhaylov S, et al. Pathologic high shear stress induces apoptosis events in human platelets. Biochem Biophys Res Commun. 2004;320(2):303-10.
7. Leytin V, Freedman J. Platelet apoptosis in stored platelet concentrates and other models. Transfus Apher Sci. 2003;28(3):285-95.
8. Leytin V, Allen DJ, Mutlu A, et al. Platelet activation and apoptosis are different phenomena: evidence from the sequential dynamics and the magnitude of responses during platelet storage. Br J Haematol. 2008;142(3):494-7.
9. Perrotta PL, Perrotta CL, Snyder EL. Apoptotic activity in stored human platelets. Transfusion. 2003;43(4):526-35.
10. Michelson A. Platelets. Amsterdam, the Netherlands, and Boston, Mass. Academic Press/Elsevier; 2007.
11. Cines DB, Pollak ES, Buck CA, et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood. 1998;91(10):3527-61.
12. Nurden AT, Nurden P. Congenital platelet disorders and understanding of platelet function. Br J Haematol. 2014;165(2):165-78.
13. Kannan M, Saxena R. Glanzmann's thrombasthenia: an overview. Clin Appl Thromb Hemost. 2009 Mar-Apr;15(2):152-65.
14. Baj-Krzyworzeka M, Baran J, Szatanek R, et al. Application of Flow Cytometry in the Studies of Microparticles. Flow Cytometry-Recent Perspectives: InTech; 2012.
15. Mody M, Lazarus A, Semple J, et al. Preanalytical requirements for flow cytometric evaluation of platelet activation: choice of anticoagulant. Transfus Med. 1999;9(2):147-54.
16. Dachary-Prigent J, Freyssinet JM, Pasquet JM, et al. Annexin V as a probe of aminophospholipid exposure and platelet membrane vesiculation: a flow cytometry study showing a role for free sulfhydryl groups. Blood. 1993;81(10):2554-65.
17. Wang H, Bang K, Blanchette VS, et al. Phosphatidylserine exposure, microparticle formation and mitochondrial depolarisation in Glanzmann thrombasthenia platelets. Thromb Haemost. 2014;111(6):1184-6.
18. Wang Z, Li S, Shi Q, et al. Calmodulin antagonists induce platelet apoptosis. Thromb Res. 2010;125(4):340-50.
19. Brown SB, Clarke MC, Magowan L, et al. Constitutive death of platelets leading to scavenger receptor-mediated phagocytosis. A caspase-independent cell clearance program. J Biol Chem. 2000; 275(8):5987-96.
20. Topalov NN, Yakimenko AO, Canault M, et al. Two types of procoagulant platelets are formed upon physiological activation and are controlled by integrin α (IIb) β (3). Arterioscler Thromb Vasc Biol. 2012;32(10):2475-83.
21. Schoenwaelder SM, Yuan Y, Josefsson EC, et al. Two distinct pathways regulate platelet phosphatidylserine exposure and procoagulant function. Blood. 2009;114(3):663-6.
22. Leung R, Gwozdz A, Wang H, et al. Persistence of procoagulant surface expression on activated human platelets: involvement of apoptosis and aminophospholipid translocase activity. J Thromb Haemost. 2007; 5(3):560-70.
23. Rand ML, Wang H, Bang K, et al. Phosphatidylserine exposure and other apoptotic‐like events in Bernard‐Soulier syndrome platelets. AmJ Hematol. 2010;85(8):584-92.
24. Leytin V, Mutlu A, Mykhaylov S, et al. The GPIIbIIIa antagonist drugs eptifibatide and tirofiban do not induce activation of apoptosis executioner caspase-3 in resting platelets but inhibit caspase-3 activation in platelets stimulated with thrombin or calcium ionophore A23187. Haematologica. 2009;94(12):1783-4.
25. Shpilberg O, Rabi I, Schiller K, et al. Patients with Glanzmann thrombasthenia lacking platelet glycoprotein α IIb β 3 (GPIIb/IIIa) and α v β 3 receptors are not protected from atherosclerosis. Circulation. 2002;105(9):1044-8.
26. Ten Cate H, Brandjes D, Smits P, et al. The role of platelets in venous thrombosis: a patient with Glanzmann's thrombasthenia and a factor V Leiden mutation suffering from deep venous thrombosis. J Thromb Haemost. 2003;1(2):394-5.
27. MR M. Microparticle Formation and Platelet Shrinkage in Type-I Glanzmann Thrombasthenia Platelets. Iran J Blood Cancer. 2014;6(4):169-75.
28. Nomura S, Komiyama Y, Murakami T, et al. Flow cytometric analysis of surface membrane proteins on activated platelets and platelet-derived microparticles from healthy and thrombasthenic individuals. Int J Hematol. 1993;58(3):203-12.
Files
IssueVol 19 No 4 (2025) QRcode
SectionOriginal Article(s)
Keywords
Apoptosis; Glanzmann thrombasthenia; Glycoprotein IIbIIIa; Flow cytometry; Microparticle
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Shahverdi E, Petz C, Hemmati2TH, Farsinezhad A, Heidari A, Faranoush M. Apoptotic Events in Type-I Glanzmann Thrombasthenia Platelets. Int J Hematol Oncol Stem Cell Res. 2025;19(4):344-353.